IRIS Accounts Production v25.1.0.734 10620297 director 1.3.24 31.12.24 31.12.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh106202972024-02-29106202972024-12-31106202972024-03-012024-12-31106202972023-02-28106202972023-03-012024-02-29106202972024-02-2910620297ns15:EnglandWales2024-03-012024-12-3110620297ns14:PoundSterling2024-03-012024-12-3110620297ns10:Director12024-03-012024-12-3110620297ns10:PrivateLimitedCompanyLtd2024-03-012024-12-3110620297ns10:SmallEntities2024-03-012024-12-3110620297ns10:AuditExempt-NoAccountantsReport2024-03-012024-12-3110620297ns10:SmallCompaniesRegimeForDirectorsReport2024-03-012024-12-3110620297ns10:SmallCompaniesRegimeForAccounts2024-03-012024-12-3110620297ns10:FullAccounts2024-03-012024-12-3110620297ns10:CompanySecretary12024-03-012024-12-3110620297ns10:RegisteredOffice2024-03-012024-12-3110620297ns5:CurrentFinancialInstruments2024-12-3110620297ns5:CurrentFinancialInstruments2024-02-2910620297ns5:Non-currentFinancialInstruments2024-12-3110620297ns5:Non-currentFinancialInstruments2024-02-2910620297ns5:ShareCapital2024-12-3110620297ns5:ShareCapital2024-02-2910620297ns5:RetainedEarningsAccumulatedLosses2024-12-3110620297ns5:RetainedEarningsAccumulatedLosses2024-02-2910620297ns5:LeaseholdImprovements2024-03-012024-12-3110620297ns5:PlantMachinery2024-03-012024-12-3110620297ns5:FurnitureFittings2024-03-012024-12-3110620297ns5:ComputerEquipment2024-03-012024-12-3110620297ns5:LeaseholdImprovements2024-02-2910620297ns5:PlantMachinery2024-02-2910620297ns5:FurnitureFittings2024-02-2910620297ns5:LeaseholdImprovements2024-12-3110620297ns5:PlantMachinery2024-12-3110620297ns5:FurnitureFittings2024-12-3110620297ns5:LeaseholdImprovements2024-02-2910620297ns5:PlantMachinery2024-02-2910620297ns5:FurnitureFittings2024-02-2910620297ns5:MotorVehicles2024-02-2910620297ns5:ComputerEquipment2024-02-2910620297ns5:MotorVehicles2024-03-012024-12-3110620297ns5:MotorVehicles2024-12-3110620297ns5:ComputerEquipment2024-12-3110620297ns5:MotorVehicles2024-02-2910620297ns5:ComputerEquipment2024-02-2910620297ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3110620297ns5:WithinOneYearns5:CurrentFinancialInstruments2024-02-29106202971ns10:Director12024-02-29106202971ns10:Director12023-02-28106202971ns10:Director12024-03-012024-12-31106202971ns10:Director12023-03-012024-02-29106202971ns10:Director12024-12-31106202971ns10:Director12024-02-29
REGISTERED NUMBER: 10620297 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD 1 MARCH 2024 TO 31 DECEMBER 2024

FOR

CAMBRIDGE GLYCOSCIENCE LIMITED

CAMBRIDGE GLYCOSCIENCE LIMITED (REGISTERED NUMBER: 10620297)






CONTENTS OF THE FINANCIAL STATEMENTS
for the Period 1 March 2024 to 31 December 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


CAMBRIDGE GLYCOSCIENCE LIMITED

COMPANY INFORMATION
for the Period 1 March 2024 to 31 December 2024







DIRECTOR: Dr T J Simmons





SECRETARY: The Cambridge Partnership Limited





REGISTERED OFFICE: C/o The Cambridge Partnership Ltd
The Dorothy Hodgkin Building
Babraham Research Campus, Babraham
Cambridge
Cambridgeshire
CB22 3FH





REGISTERED NUMBER: 10620297 (England and Wales)





ACCOUNTANTS: Lovetts Accountants Limited
Bridge House
25 Fiddlebridge Lane
Hatfield
Hertfordshire
AL10 0SP

CAMBRIDGE GLYCOSCIENCE LIMITED (REGISTERED NUMBER: 10620297)

BALANCE SHEET
31 December 2024

31.12.24 29.2.24
Notes £    £    £   
FIXED ASSETS
Property, plant and equipment 4 48,524 205,756

CURRENT ASSETS
Inventories 313 -
Debtors 5 510,905 574,954
Cash at bank 310,245 1,713,317
821,463 2,288,271
CREDITORS
Amounts falling due within one year 6 644,404 229,572
NET CURRENT ASSETS 177,059 2,058,699
TOTAL ASSETS LESS CURRENT
LIABILITIES

225,583

2,264,455

CREDITORS
Amounts falling due after more than one
year

7

21,622,496

21,324,162
NET LIABILITIES (21,396,913 ) (19,059,707 )

CAPITAL AND RESERVES
Called up share capital 1 1
Retained earnings (21,396,914 ) (19,059,708 )
SHAREHOLDERS' FUNDS (21,396,913 ) (19,059,707 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

CAMBRIDGE GLYCOSCIENCE LIMITED (REGISTERED NUMBER: 10620297)

BALANCE SHEET - continued
31 December 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 9 May 2025 and were signed by:





Dr T J Simmons - Director


CAMBRIDGE GLYCOSCIENCE LIMITED (REGISTERED NUMBER: 10620297)

NOTES TO THE FINANCIAL STATEMENTS
for the Period 1 March 2024 to 31 December 2024

1. STATUTORY INFORMATION

Cambridge Glycoscience Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - Straight line over 4 years
Plant and machinery - Straight line over 3 years
Fixtures and fittings - Straight line over 3 years
Computer equipment - Straight line over 3 years

Stocks
Inventories are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


CAMBRIDGE GLYCOSCIENCE LIMITED (REGISTERED NUMBER: 10620297)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Period 1 March 2024 to 31 December 2024

2. ACCOUNTING POLICIES - continued

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern
As at 31 December 2024, the company has an excess of current liabilities over current assets and is dependent upon the continued support of its directors and parent company. Therefore, the accounts have been prepared on a going concern basis in the knowledge this support will continue.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 14 (2024 - 25 ) .

4. PROPERTY, PLANT AND EQUIPMENT
Improvements Fixtures
to Plant and and
property machinery fittings
£    £    £   
COST
At 1 March 2024 73,758 879,716 46,126
Additions - - -
At 31 December 2024 73,758 879,716 46,126
DEPRECIATION
At 1 March 2024 45,255 733,063 37,210
Charge for period 18,439 112,128 8,576
At 31 December 2024 63,694 845,191 45,786
NET BOOK VALUE
At 31 December 2024 10,064 34,525 340
At 29 February 2024 28,503 146,653 8,916

CAMBRIDGE GLYCOSCIENCE LIMITED (REGISTERED NUMBER: 10620297)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Period 1 March 2024 to 31 December 2024

4. PROPERTY, PLANT AND EQUIPMENT - continued

Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1 March 2024 33,000 84,960 1,117,560
Additions - 2,483 2,483
At 31 December 2024 33,000 87,443 1,120,043
DEPRECIATION
At 1 March 2024 26,951 69,325 911,804
Charge for period 6,049 14,523 159,715
At 31 December 2024 33,000 83,848 1,071,519
NET BOOK VALUE
At 31 December 2024 - 3,595 48,524
At 29 February 2024 6,049 15,635 205,756

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 29.2.24
£    £   
Trade debtors 77,183 23,489
Other debtors 433,722 551,465
510,905 574,954

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 29.2.24
£    £   
Trade creditors 244,990 117,494
Taxation and social security 183,839 38,916
Other creditors 215,575 73,162
644,404 229,572

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.12.24 29.2.24
£    £   
Amounts owed to group undertakings 21,622,496 21,324,162

8. SECURED DEBTS

The parent company, Supplant Inc, has a loan from Western Technology Inc of $3,689,457 (February 2024: $4,887,542). The lender, as security for that loan, has the benefit of a fixed and floating charge over all the assets of both the parent and the company.

CAMBRIDGE GLYCOSCIENCE LIMITED (REGISTERED NUMBER: 10620297)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Period 1 March 2024 to 31 December 2024

9. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the period ended 31 December 2024 and the year ended 29 February 2024:

31.12.24 29.2.24
£    £   
Dr T J Simmons
Balance outstanding at start of period 69,951 41,562
Amounts advanced 538 74,889
Amounts repaid (70,489 ) (46,500 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of period - 69,951

10. ULTIMATE CONTROLLING PARTY

The controlling party is Supplant Inc, incorporated in Delaware, USA.

The ultimate controlling party is Dr T J Simmons.